A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.
Patheon announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined, the company reports in a statement.
J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering.
In March 2014, Patheon completed its $2.65 billion merger with DSM Pharmaceutical Products (DPP) to form DPx.
In April 2015, Patheon completed the acquisition of IRIX Pharmaceuticals, a Florence, SC company that specializes in API development and manufacturing. This follows the March 2015 acquisition of Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving drug bioavailability.
Source: Patheon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.